

For Immediate Release

Anodyne Therapy receives U.S. Patent for Treating Neuropathy Using a Photo Energy Device

TAMPA, FL - August 25, 2003 - Anodyne[®] Therapy, LLC announced today that it received a U.S. Patent (Patent No. 6,607,550) entitled "Method of Treating Neuropathy Using a Photo Energy Device." Neuropathy is nerve damage often associated with diabetes, trauma and other chronic diseases. Symptoms include numbness and/or pain in the feet, legs and hands. Neuropathy from some causes like diabetes is very difficult to treat and is a major contributing factor to foot wounds, amputations and falls. The cost of diabetic neuropathy alone to the U.S. healthcare system has been reported to exceed \$37 billion per year.

"We are very pleased with the issuance of this additional patent, which recognizes our unique franchise in the clinical use of light-based technology as a method for reducing sensory impairments due to diabetic and other neuropathies," said Craig Turtzo, CEO. "Our Anodyne Therapy System is currently being used by more than 1000 physicians and therapists to assist them in improving functional outcomes for patients suffering from a broad range of health problems. Most significantly, numerous completed and ongoing clinical studies show promising results in improving the quality of life of people afflicted with diabetic and other neuropathies that had previously been unresponsive to other treatments."

Anodyne Therapy treatments are currently available at outpatient facilities, hospitals, nursing homes, physician offices and home health agencies nationwide. Products are also available for convenient home use. The home use product received a Medicare HCPCS Reimbursement Code in 2002. For more information, visit www.anodynetherapy.com.

CONTACT INFORMATION:

Kim Stebbings, Vice President, Sales and Marketing

Anodyne Therapy, LLC, 13570 Wright Circle, Tampa, FL 33626

Office: 813-342-4432 ext. 122 Cell: 720-560-0533 Email: kimstebbing@aol.com

###